For immunochemical detection of PAD3
Related Products
Measurement and Detection Tool(s)
10786PAD3 (human, recombinant)
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

PAD3 Monoclonal Antibody (Clone 4E5)

Item No. 24377

Technical Information
Synonyms
  • PADI3
  • PDI3
  • Peptidylarginine Deiminase 3
  • Protein Arginine Deiminase 3
Immunogen
Full length recombinant PAD3
Clone Designation
4E5
MW
~74 kDa
100 µg of protein G affinity-purified monoclonal antibody
Storage Buffer
PBS, pH 7.2, 50% glycerol with 0.02% sodium azide
Host
Mouse
Isotype
IgG1
Applications
ELISA, IF, WB
Cross Reactivity
(+) PAD3(-) PAD1(-) PAD2(-) PAD4
Species Reactivity
(+) Human
UniProt Accession №
Q9ULW8
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Protein arginine deiminase 3 (PAD3) catalyzes the conversion of arginine residues to citrulline within its cellular protein substrates, which include S100A3, trichohyalin, and filaggrin, resulting in the loss of a positive charge, which can alter protein structure and/or function.1 It exists as a homodimer and is composed of a C-terminal catalytic domain and an N-terminal domain that contains two immunoglobulin G (IgG) subdomains.2 PAD3 is primarily expressed by differentiated keratinocytes in the epidermis and hair follicles where it has roles in the shaping and mechanical strengthening of hair.2,3 It is also expressed by neural stem cells where it modulates cell death by regulating the nuclear translocation of apoptosis-inducing factor (AIF), in mammary glands where it citrullinates proteins during lactation, and cancer cells where it promotes cancer cell invasion.4,5,6 Mutations in PADI3 are associated with uncombable hair syndrome. Cayman's PAD3 Monoclonal Antibody (Clone 4E5) can be used for ELISA, Immunofluorescence (IF) and Western blot (WB) applications. The antibody recognizes PAD3 at ~74 kDa from human samples.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. van Beers, J.J.B.C., Zendman, A.J.W., Raijmakers, R., et alPeptidylarginine deiminase expression and activity in PAD2 knock-out and PAD4-low mice. Biochimie 95(2), 299-308 (2013).

    2. Funabashi, K., Sawata, M., Nagai, A., et alStructures of human peptidylarginine deiminase type III provide insights into substrate recognition and inhibitor design. Arch. Biochem. Biophys. 708, 108911 (2021).

    3. Basmanav, F.B.Ü., Cau, L., Tafazzoli, A., et alMutations in three genes encoding proteins involved in hair shaft formation cause uncombable hair syndrome. Am. J. Cancer Res. 99(6), 1292-1304 (2016).

    4. U, K.P., Subramanian, V., Nicholas, A.P., et alModulation of calcium-induced cell death in human neural stem cells by the novel peptidylarginine deiminase-AIF pathway. Biochim. Biophys. Acta 1843(6), 1162-1171 (2014).

    5. Li, G., Hayward, I.N., Jenkins, B.R., et alPeptidylarginine deiminase 3 (PAD3) is upregulated by prolactin stimulation of CID-9 cells and expressed in the lactating mouse mammary gland. PLoS One 11(1), e0147503 (2016).

    6. Uysal-Onganer, P., D'Alessio, S., Mortoglou, M., et alPeptidylarginine deiminase inhibitor application, using Cl-amidine, PAD2, PAD3 and PAD4 isozyme-specific inhibitors in pancreatic cancer cells, reveals roles for PAD2 and PAD3 in cancer invasion and modulation of extracellular vesicle signatures. Int. J. Mol. Sci. 22(3), 1396 (2021).